Rigel Pharmaceuticals (FRA:RI2) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.80
GF Value €24.49
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Tariff Resilience Score?

Rigel Pharmaceuticals FRA:RI2 +1.08% 76 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.49. The stock has 7 warning signs investors should review. Among 1,374 Biotechnology companies, Rigel Pharmaceuticals ranks better than 90.39% on this metric.

Rigel Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Rigel Pharmaceuticals has Rigel Pharmaceuticals has limited exposure to tariffs due to its focus on pharmaceuticals, which are often exempt from tariffs. Its supply chain is primarily domestic, reducing vulnerability to international trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Rigel Pharmaceuticals might have Highly Resilient.

Rigel Pharmaceuticals  (FRA:RI2) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Rigel Pharmaceuticals Tariff Resilience Score Related Terms

FRA:RI2 vs CADL, IMMX, AURA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Tariff Resilience Score falls into.


FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Rigel Pharmaceuticals (FRA:RI2) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Rigel Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Rigel Pharmaceuticals' Tariff Resilience Score too high?
Rigel Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Rigel Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Tariff Resilience Score compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #132 out of 1374 companies for Tariff Resilience Score. This places Rigel Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Rigel Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Tariff Resilience Score of 7. The stock's GF Value™ is €24.49, compared to a current price of €33.80 — trading 38% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.80 is trading 38% above its estimated GF Value™ of €24.49.

Key valuation signals for FRA:RI2:

  • Tariff Resilience Score: 7
  • GF Value™: €24.49 vs. price of €33.80 (38% above fair value)
  • GF Score™: 76/100 with 7 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.80
Price
€24.49
GF Value